Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and Efficacy
The proposed open-label, controlled study at the Johns Hopkins Center for Psychedelic and Consciousness Research (CPCR) will test the following primary hypotheses in adult patients with chronic PTSD who are currently taking a serotonin reuptake inhibitor: psilocybin therapy will be feasible and safe for participants, significantly remediate PTSD symptoms, and enhance wellbeing and quality of life. In addition, the study will examine whether elements of evidence-based trauma-focused psychotherapy enhance treatment response when paired with psilocybin.
- Status
- active
- Phase
- Phase 1
- Institution
- Johns Hopkins University
- Principal investigator
- Sandeep Nayak, MD
- Start date
- 2024-06-07
- End date
- 2027-05-01
- Registry ID
- NCT06407635
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.